Clinical Trial

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Study acronym: INSIGHT
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial aims to investigate a potential enhancement of IMP321 immune-activating effects by new routes of administration: direct injection of IMP321 into the tumor tissue; intra-peritoneal therapy; combination of chemotherapy and/or immunotherapy/targeted therapy with active immunotherapy
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2017-08-14; most recent amendment 2026-02-18.
Status change: Recruiting → Active, Not Recruiting 2026-02-18
Status change: Completed → Recruiting 2021-07-12
Status change: Active, Not Recruiting → Completed 2021-05-20
Status change: Recruiting → Active, Not Recruiting 2020-05-26
Status change: Not Yet Recruiting → Recruiting 2017-09-13
Trial Details
NCT Number NCT03252938
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Immutep S.A.S.
Conditions Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma, Urothelial Carcinoma
Enrollment 83 participants
Start Date 2017-08-15
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-19